<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher C Glisson, DO, MS, FAAN</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H680778627"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting optic nerves and the spinal cord.</p><p>The treatment and prognosis of NMOSD will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, diagnosis of NMOSD are reviewed separately. (See  <a class="medical medical_review" href="/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H2933766933"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>The rationale for treatment of acute and recurrent attacks in NMOSD is based upon evidence that humoral autoimmunity plays a role in the pathogenesis of NMOSD and is driven by the high attack-related disability, poor prognosis, and overall high risk of mortality in untreated patients [<a href="#rid1">1,2</a>]. Thus, long-term immunotherapy is indicated for the prevention of attacks as soon as the diagnosis of NMOSD is made. (See <a class="local">'Attack prevention'</a> below.)</p><p class="headingAnchor" id="H100694174"><span class="h1">ACUTE ATTACKS</span></p><p class="headingAnchor" id="H2028517265"><span class="h2">Definition</span><span class="headingEndMark"> — </span>An attack of NMOSD is defined by objective neurologic worsening reflecting focal or multifocal central nervous system inflammation that develops acutely or subacutely in the absence of fever or infection, with a duration of at least 24 hours and occurring more than 30 days after the previous attack [<a href="#rid3">3</a>]. This definition is similar to the definition of a multiple sclerosis (MS) relapse.</p><p class="headingAnchor" id="H515815858"><span class="h2">Acute treatment</span><span class="headingEndMark"> — </span>All patients with suspected NMOSD require treatment for acute attacks.</p><p class="headingAnchor" id="H1889061698"><span class="h3">Glucocorticoid treatment</span><span class="headingEndMark"> — </span>We suggest initial treatment with high-dose intravenous <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (1 gram daily for three to five consecutive days), in agreement with expert panel recommendations and based upon studies of MS and idiopathic optic neuritis [<a href="#rid1">1,4,5</a>]. (See  <a class="medical medical_review" href="/d/html/1698.html" rel="external">"Treatment of acute exacerbations of multiple sclerosis in adults", section on 'Initial therapy with glucocorticoids'</a> and  <a class="medical medical_review" href="/d/html/5252.html" rel="external">"Optic neuritis: Prognosis and treatment", section on 'Treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response rates</strong> – Observational evidence suggests that the response to initial treatment of an NMOSD attack is often suboptimal and that most patients will benefit from a second therapy. In a retrospective report of 871 attacks in 185 patients with NMOSD, the first treatment course (consisting of high-dose intravenous glucocorticoid in 84 percent of patients, plasma exchange in 8 percent, and other treatments in the remainder) was associated with complete remission in only 19 percent of patients and a partial remission or no remission in 65 and 16 percent, respectively [<a href="#rid6">6</a>]. Additional treatment courses, particularly a second treatment course, was associated with an increased remission rate. Plasma exchange was used more frequently in second (34 percent) and subsequent (50 percent or more) treatment courses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seronegative NMOSD</strong> – Seronegative NMOSD is managed in the same way as seropositive NMOSD.</p><p></p><p class="headingAnchor" id="H1144389570"><span class="h3">Adjunctive plasma exchange</span><span class="headingEndMark"> — </span>For patients with severe symptoms or vision loss that is poorly responsive to glucocorticoids, therapeutic plasma exchange is the suggested concomitant or rescue treatment [<a href="#rid1">1,4,5</a>]. Exchanges are carried out every other day up to a total of seven exchanges.</p><p>Limited retrospective and uncontrolled data suggest that patients with severe attacks of NMOSD do better if plasma exchange is started early as adjunctive therapy with glucocorticoids. One report of patients with severe attacks (defined by an Expanded Disability Status Scale  (<a class="graphic graphic_table graphicRef57639" href="/d/graphic/57639.html" rel="external">table 1</a>) score ≥4 and/or visual acuity ≤20/200) found that initial treatment with intravenous glucocorticoids plus early therapeutic plasma exchange was associated with improved outcomes compared with delayed initiation of plasma exchange following glucocorticoid treatment [<a href="#rid7">7</a>].</p><p>Intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> has not been specifically evaluated for acute attacks of NMOSD and is rarely used in this setting.</p><p class="headingAnchor" id="H3952642674"><span class="h1">ATTACK PREVENTION</span></p><p class="headingAnchor" id="H462084728"><span class="h2">Approach</span><span class="headingEndMark"> — </span>Because the natural history of NMOSD is one of stepwise deterioration due recurrent attacks and accumulated disability, long-term immunotherapy is indicated for the prevention of attacks as soon as the diagnosis of NMOSD is made [<a href="#rid1">1,5,8</a>].</p><p>For patients with NMOSD who are seropositive for aquaporin-4 (AQP4)-immunoglobulin G (IgG) antibodies, we suggest treatment with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, <a class="drug drug_general" data-topicid="128443" href="/d/drug information/128443.html" rel="external">inebilizumab</a>, <a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">satralizumab</a>, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>, or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, rather than other immunosuppressive agents. However, the optimal drug regimen and treatment duration are yet to be determined.</p><p><a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a>, <a class="drug drug_general" data-topicid="128443" href="/d/drug information/128443.html" rel="external">inebilizumab</a>, and <a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">satralizumab</a> are approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of AQP4-antibody positive NMOSD. In mid-2023, the EMA also approved <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a> for the treatment of adults with AQP4-seropositive NMOSD [<a href="#rid9">9</a>]. All these agents are very expensive; many clinicians use <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, or other off-label immunotherapies for patients who meet NMOSD diagnostic criteria with or without AQP4-IgG seropositivity.</p><p class="headingAnchor" id="H231971115"><span class="h2">Immunotherapies</span></p><p class="headingAnchor" id="H959300908"><span class="h3">Eculizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> is a humanized antibody that binds to the complement component C5 and inhibits the formation of C5b-induced membrane attack complex.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> is administered intravenously at 900 mg weekly for the first four doses, followed by maintenance dosing of 1200 mg every two weeks beginning at week 5.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> infusions are generally well tolerated. Commonly reported adverse events in clinical trials included headache, upper respiratory tract infections, back pain, and nausea. However, eculizumab treatment is associated with an increased risk of infection with <em>Neisseria meningitidis</em>; patients should be immunized with meningococcal vaccines and receive daily antimicrobial prophylaxis, as described separately.</p><p></p><p class="bulletIndent1">In the United States, <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> is available only through a restricted program under a Risk Evaluation and Mitigation Strategy. (See  <a class="medical medical_review" href="/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Patients receiving C5 inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – High-quality data support the effectiveness of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>. In the PREVENT randomized controlled trial of 143 patients with NMOSD who were seropositive for AQP4-IgG antibodies, treatment with intravenous eculizumab reduced the risk of relapse; the annualized relapse rates for the eculizumab and placebo groups were 0.02 and 0.35 (absolute risk reduction [ARR] 33 percent, rate ratio 0.04, 95% CI 0.01-0.15) [<a href="#rid10">10</a>]. Most patients in the trial were also taking concomitant immunotherapy (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, glucocorticoids, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil) but not <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, which was excluded because its mechanism of action is incompatible with eculizumab. Data from an open-label extension phase of the trial suggested that eculizumab treatment was associated with a sustained reduction of the relapse rate [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H1575471825"><span class="h3">Inebilizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="128443" href="/d/drug information/128443.html" rel="external">Inebilizumab</a> is a humanized monoclonal antibody that binds to the CD19 surface antigen of B cells, thereby depleting a wide range of lymphocytes derived from B cell lineage, including peripheral blood CD20 plasmablasts and plasma cells [<a href="#rid12">12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – <a class="drug drug_general" data-topicid="128443" href="/d/drug information/128443.html" rel="external">Inebilizumab</a> is given by intravenous infusion as an initial dose of 300 mg, followed two weeks later by a second 300 mg dose [<a href="#rid13">13</a>]. Thereafter, inebilizumab is given as 300 mg infusion every six months, starting from the first infusion. Patients should be premedicated with a glucocorticoid (eg, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 80 to 125 mg), an antihistamine (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> 25 to 50 mg), and an antipyretic (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> 500 to 650 mg) prior to every inebilizumab infusion. Patients should be monitored for infusion reactions during and for at least one hour after the end of the infusion. Administration of inebilizumab should be delayed for patients with active infection until the infection resolves. Patients should be screened for hepatitis B virus and tuberculosis before the first dose. Immunoglobulin levels should be monitored before treatment and at regular intervals during and after treatment. Flow cytometric analysis with an anti-CD20 antibody should be used to determine that circulating B cells continue to be depleted just before the next infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse reactions</strong> – The most common adverse reactions in the randomized trial were urinary tract infection, headache, arthralgia, nausea, and back pain [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Contraindications to <a class="drug drug_general" data-topicid="128443" href="/d/drug information/128443.html" rel="external">inebilizumab</a> are active hepatitis B infection, active or untreated latent tuberculosis, and previous life-threatening reaction to inebilizumab infusion [<a href="#rid13">13</a>]. Use during pregnancy is not advised because of potential harm to the fetus or newborn baby. Vaccination with live or live-attenuated vaccines is not recommended during or after treatment until B cell repletion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="128443" href="/d/drug information/128443.html" rel="external">Inebilizumab</a> was evaluated in the N-MOmentum trial of 230 patients with NMOSD (with 92 percent seropositive for anti-AQP4 antibodies) who were randomly assigned in a 3:1 ratio to intravenous treatment with inebilizumab 300 mg (n = 175) or to placebo (n = 56) administered on days 1 and 15 [<a href="#rid14">14</a>]. The trial was stopped early after an interim analysis at 6.5 months determined efficacy as defined by fewer attacks among patients assigned to inebilizumab compared with those assigned to placebo (12 versus 39 percent, ARR 27 percent, hazard ratio [HR] 0.27, 95% CI 0.15-0.50). The rate of all adverse events and serious adverse events was similar between the inebilizumab and placebo groups. Limitations of this trial include the short duration of clinical follow-up and early stopping, which can lead to an overestimate of the treatment effect. Based upon these data, inebilizumab was approved by the FDA in June 2020 for the treatment of adults with NMOSD who are seropositive for anti-AQP4 antibodies [<a href="#rid15">15</a>]. However, further study is needed to establish the long-term efficacy and safety of inebilizumab relative to <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, which has also shown efficacy in NMOSD.</p><p></p><p class="headingAnchor" id="H3034527192"><span class="h3">Satralizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">Satralizumab</a> is a humanized monoclonal antibody that binds interleukin-6 (IL-6) receptors, thereby suppressing inflammation mediated by IL-6 signaling pathways.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – <a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">Satralizumab</a> is given by subcutaneous injection with a loading dose of 120 mg at weeks 0, 2, and 4, followed by a maintenance dose of 120 mg every four weeks [<a href="#rid16">16</a>]. Screening for hepatitis B virus and tuberculosis are required before the first dose. Active infection should be excluded prior to every dose; treatment should be delayed for patients with active infection until resolved. Liver transaminase levels (ALT and AST) should be checked prior to first dose, and ALT, AST, and neutrophil counts should be monitored during treatment. Live or live-attenuated vaccines are not recommended during treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse effects with <a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">satralizumab</a> are nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea. Satralizumab is contraindicated for patients with active hepatitis B infection, active or untreated latent tuberculosis, or known hypersensitivity to satralizumab.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Efficacy of <a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">satralizumab</a> was demonstrated in two randomized controlled trials [<a href="#rid17">17,18</a>]. In the first trial, 83 patients with NMOSD were randomly assigned to subcutaneous injection with satralizumab 120 mg or placebo at weeks 0, 2, and 4, and every four weeks thereafter, in addition to their baseline immunosuppressant therapy [<a href="#rid17">17</a>]. At a median blinded treatment duration of 107 weeks, there were fewer relapses among patients assigned to satralizumab compared with those assigned to placebo (20 versus 43 percent, ARR 23 percent, HR 0.38, 95% CI 0.16-0.88). In the subgroup of 55 patients who were seropositive for anti-AQP4 antibodies, relapses were less frequent among patients assigned to satralizumab compared with placebo (11 versus 43 percent, ARR 32 percent, HR 0.21, 95% CI 0.06-0.75). In the subgroup of 28 patients who were seronegative for anti-AQP4 antibodies, the number of relapses was similar among patients assigned to satralizumab compared with placebo (36 versus 43 percent, ARR 7 percent, HR 0.66, 95% CI 0.2-2.24). For the entire cohort, the rate of all adverse events and serious adverse events was similar between the satralizumab and placebo groups.</p><p></p><p class="bulletIndent1">The second trial of 95 patients with NMOSD was similar in design to the first, except that concomitant immunosuppressant therapy was not allowed [<a href="#rid18">18</a>]. <a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">Satralizumab</a> monotherapy reduced the rate of relapse (30 percent, versus 50 percent for placebo, ARR 20 percent, HR 0.45, 95% CI 0.23-0.89) and was generally well tolerated.</p><p></p><p class="headingAnchor" id="H2587645342"><span class="h3">Ravulizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">Ravulizumab</a> is a humanized antibody that binds to the same complement component C5 epitope as <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, thereby inhibiting the formation of C5b-induced membrane attack complex. Ravulizumab has a longer half-life than eculizumab, which permits less frequent maintenance administration for ravulizumab (every eight weeks) compared with eculizumab (every two weeks) [<a href="#rid19">19</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – For patients with NMOSD and no prior treatment, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a> is given intravenously with a weight-based loading dose of 2400 to 3600 mg on day one, followed by a weight-based maintenance dose of 3000 to 3600 mg once every eight weeks, starting two weeks after the loading dose [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Patients should be immunized with meningococcal vaccines at least two weeks prior to administering the first dose of <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Meningococcal infections occurred in two patients (3 percent) treated with <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a> in the CHAMPION-NMOSD trial despite prior vaccination against <em>Neisseria meningitidis</em>; other common adverse events included COVID-19 in 24 percent and headache in 24 percent [<a href="#rid20">20</a>]. There were no deaths. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The open-label CHAMPION-NMOSD trial enrolled adult patients with AQP4-antibody positive NMOSD (n = 58) who were treated with <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a> [<a href="#rid20">20</a>]. A concurrent placebo control group was considered unethical given the availability of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>. Therefore, a historical placebo control group (n = 47) from the eculizumab PREVENT trial was used as the comparator group. The median follow-up period for the ravulizumab and external control groups was 73.5 and 36.0 weeks, respectively. No patients in the ravulizumab group had an adjudicated on-trial relapse, compared with 20 patients in the historical placebo group (hazard ratio 0.014, 95% CI 0.000-0.103). Although cross-trial comparisons represent low-quality evidence and can be misleading, the risk reduction observed with ravulizumab in the CHAMPION-NMOSD trial was consistent with that observed with eculizumab in the PREVENT trial [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H2848132396"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is a chimeric monoclonal antibody that causes B cell depletion by binding to the CD20 antigen of B cell lymphocytes and to Fc receptors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is started with two 1 g infusions separated by a two-week interval, followed by a 1 g infusion every six months or earlier if CD19+ lymphocytes are &gt;0.1 percent of total lymphocytes [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse reactions</strong> – Potential adverse effects include infusion reactions, hypogammaglobulinemia, infection, reactivation of hepatitis B, and neutropenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In an open-label randomized trial of 86 patients who had NMOSD with or without AQP4 antibodies, the annualized relapse rate at 12 months was significantly reduced for patients assigned to <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> compared with those assigned to <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">Evidence of efficacy is also supported by results from a small trial in Japan that randomly assigned 38 patients (36 women and 2 men) with AQP4 antibody-positive NMOSD in a 1:1 ratio to treatment with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or placebo [<a href="#rid23">23</a>]. All the patients in the trial had relatively mild disease and were on concomitant oral glucocorticoids throughout the trial. Intravenous rituximab was loaded at 375 mg/m<sup>2</sup> every week for four weeks, followed by a maintenance phase of rituximab 2000 mg (given as two 1000 mg doses separated by two weeks) at 24 and 48 weeks after randomization. At a median follow-up of 72 weeks, there were no relapses in patients assigned to rituximab and seven relapses in patients assigned to placebo (0 versus 37 percent, group difference, 36.8 percent, 95% CI 12.3-65.5 percent). One patient assigned to rituximab had an infusion reaction, but adverse events were otherwise similar in the two treatment groups. The small size of this trial prevents definitive conclusions, and additional research is needed to confirm safety and efficacy of rituximab for NMOSD.</p><p></p><p class="bulletIndent1">One small observational study of patients with NMOSD who were seropositive for AQP4 or myelin oligodendrocyte glycoprotein antibodies found that <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> treatment was associated with a lower risk of relapse compared with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [<a href="#rid24">24</a>], and rituximab treatment was associated with a lower relapse rate compared with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> in a small observational study of patients with NMOSD [<a href="#rid25">25</a>]. A systematic review of observational studies found that rituximab was associated with a reduced frequency of relapses and reduced neurologic disability in patients with NMOSD, but also noted concerns about the safety profile of rituximab [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H3203422111"><span class="h3">Tocilizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> is a humanized IL-6 receptor antagonist.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – The dose of <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> is 8 mg/kg (maximum 800 mg) given intravenously every four weeks [<a href="#rid27">27</a>]. Interruption of dosing may be needed for laboratory abnormalities such as elevated liver enzymes, neutropenia, or thrombocytopenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> may cause dyslipidemia but is generally well tolerated. The most common adverse effects are upper respiratory infection, headache, hypertension, elevated alanine aminotransferase, and injection site reactions. Other adverse effects include neutropenia, thrombocytopenia, and serious infections, including mycobacterial and other opportunistic infections. Intestinal perforations have been reported, especially in older patients and in those with a history of diverticulitis, which is a contraindication to the use of tocilizumab.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In an open-label trial of 118 patients with NMOSD, intravenous <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> (8 mg/kg every four weeks) was superior to <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> for reducing the relapse rate [<a href="#rid27">27</a>]. Tocilizumab treatment has also been associated with clinical stabilization or improvement in a small number of patients with refractory NMOSD who failed one or more of the "standard" immunosuppressive treatments (eg, glucocorticoids, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>) [<a href="#rid28">28-32</a>].</p><p></p><p class="headingAnchor" id="H186492394"><span class="h3">Other immunotherapies</span><span class="headingEndMark"> — </span>The evidence of efficacy for systemic immunotherapy in preventing NMOSD attacks comes mainly from observational studies of agents including <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> [<a href="#rid33">33,34</a>], <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [<a href="#rid35">35,36</a>], <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid37">37,38</a>], <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> [<a href="#rid39">39</a>], and oral glucocorticoids [<a href="#rid40">40</a>]. Among these, the agents most often considered as effective treatments for NMOSD are azathioprine and mycophenolate mofetil [<a href="#rid4">4,41,42</a>].</p><p>One retrospective, nonrandomized study analyzed relapses among patients with NMOSD who were treated with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and concomitant <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (n = 32) for at least six months, or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (n = 28) for at least six months, or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (n = 30) for at least one month, and followed up after treatment for at least six months [<a href="#rid43">43</a>]. Treatment with these agents was associated with significant reductions of 72 to 88 percent in annualized relapse rates compared with baseline. As an example, the annualized relapse rate decreased from 2.26 before azathioprine treatment to 0.63 after treatment, a reduction of 72 percent. Treatment failure, defined as the development of any new central nervous system inflammatory event, varied from 33 to 53 percent. The retrospective design of these studies limits the strength of the findings.</p><p>In an observational study of five Chinese patients with highly active NMOSD that was poorly responsive to "standard" immunosuppressive agents, treatment with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> (a proteosome inhibitor that depletes plasma cells) was associated with relapse-free status in four and clinical stabilization in all five [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H879902030"><span class="h2">Medications to avoid</span><span class="headingEndMark"> — </span>Limited observational evidence suggests that treatment of NMOSD with interferon beta, <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>, or <a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">fingolimod</a> is <strong>not</strong> effective and may be harmful [<a href="#rid45">45-50</a>]. There is no published evidence regarding the treatment of NMOSD with <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a>.</p><p class="headingAnchor" id="H844598824"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>Immunosuppression is usually continued for at least five years for patients who are seropositive for AQP4-IgG antibodies, including those presenting with a single attack, because they are at high risk for relapse or conversion to NMOSD [<a href="#rid51">51</a>]. However, many experts suggest that life-long therapy is appropriate, given the often-devastating nature of the disease.</p><p class="headingAnchor" id="H2971386599"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H2095126209"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>The natural history of NMOSD is one of stepwise deterioration due to accumulating visual, motor, sensory, and bladder deficits from recurrent attacks. Most acute attacks or relapses worsen over days to a nadir and recover over several weeks to months with significant sequelae. There is no clear progressive phase, as occurs in multiple sclerosis. (See  <a class="medical medical_review" href="/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis", section on 'Relapsing clinical course'</a>.)</p><p>Although definitive proof is lacking, it is likely that treatment of acute attacks with glucocorticoids and/or plasma exchange and preventive treatment with immunotherapies has improved long-term outcomes of NMOSD [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H3216295017"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Mortality rates are high in NMOSD, most frequently secondary to neurogenic respiratory failure, which occurs with extension of cervical lesions into the brainstem or from primary brainstem lesions [<a href="#rid1">1</a>]. Cohort studies published from 2003 to 2009 of North American, Brazilian, and French West Indies populations reported mortality rates of 32 percent, 50 percent, and 25 percent, respectively, in NMOSD [<a href="#rid53">53-55</a>]. These studies may be biased towards more severe cases. Progress in the diagnosis and treatment of NMOSD is expected to decrease mortality rates.</p><p class="headingAnchor" id="H3018265235"><span class="h2">Prognostic markers</span><span class="headingEndMark"> — </span>Predictors of a worse prognosis include the number of relapses within the first two years, the severity of the first attack, older age at disease onset, and (perhaps) an association with other autoimmune disorders including autoantibody status [<a href="#rid55">55-58</a>]. These prognostic factors need to be confirmed in larger independent prospective studies.</p><p>The aquaporin-4 (AQP4) autoantibody (NMO-immunoglobulin G [IgG]) may be a marker for disease course and prognosis [<a href="#rid59">59-61</a>], though the available data are inconsistent [<a href="#rid62">62</a>]. In patients with recurrent optic neuritis, retrospective evidence suggests that AQP4-IgG seropositivity is associated with poor visual outcome and development of NMOSD [<a href="#rid60">60</a>]. A prospective study of 29 patients presenting with longitudinally extensive spinal cord lesions found 55 percent of the patients seropositive for AQP4-IgG relapsed within one year or converted to NMOSD, while none of the seronegative patients relapsed [<a href="#rid61">61</a>]. By contrast, a subsequent report noted that seronegative and seropositive NMOSD were similar in terms of relapse rate, severity, and long-term outcomes [<a href="#rid62">62</a>]. The discrepancy in these results may be due to differences in the determination of antibodies (cell-based versus enzyme-linked immunosorbent assays) and perhaps intermixing of patients with AQP4-seropositive NMOSD and patients with seronegative NMOSD who would now be identified as seropositive for myelin oligodendrocyte glycoprotein-IgG antibody, as well as with patients who have antibodies not yet identified.</p><p class="headingAnchor" id="H3456736555"><span class="h2">NMOSD in pregnancy</span><span class="headingEndMark"> — </span>There are only limited and retrospective data on the relationship of NMOSD and pregnancy. These suggest that NMOSD is associated with an increased risk of miscarriage [<a href="#rid63">63</a>] and that the annualized relapse rate of NMOSD is increased in the first three to six months of the postpartum period [<a href="#rid64">64-67</a>].</p><p class="headingAnchor" id="H836037455"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H2955049024"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of acute attacks</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid therapy</strong> – For patients with acute or recurrent attacks of NMOSD, we suggest initial treatment with high-dose intravenous <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (1 gram daily for three to five consecutive days) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), with a low threshold for rapid initiation of plasma exchange. (See <a class="local">'Glucocorticoid treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjunctive plasma exchange</strong> – For patients with severe symptoms or poorly responsive to glucocorticoids, we suggest treatment with plasma exchange (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Plasma exchange may be more effective if started early as adjunctive therapy with glucocorticoids. (See <a class="local">'Adjunctive plasma exchange'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indication for preventive therapy</strong> – For patients with <strong>seropositive</strong> NMOSD, we recommend long-term immunotherapy (eg, <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, <a class="drug drug_general" data-topicid="128443" href="/d/drug information/128443.html" rel="external">inebilizumab</a>, <a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">satralizumab</a>, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>, or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>) to reduce the risk of relapse as soon as the diagnosis of NMOSD is made. For patients with <strong>seronegative</strong> NMOSD, we suggest long-term immunotherapy (eg, eculizumab, inebilizumab, satralizumab, or rituximab) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of agent</strong> – For patients with NMOSD who are seropositive for aquaporin-4 (AQP4)-immunoglobulin G (IgG) antibodies, we suggest treatment with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, <a class="drug drug_general" data-topicid="128443" href="/d/drug information/128443.html" rel="external">inebilizumab</a>, <a class="drug drug_general" data-topicid="129293" href="/d/drug information/129293.html" rel="external">satralizumab</a>, or <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>, where available, rather than other immunosuppressive agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Several immunotherapies (eculizumab, inebilizumab, and satralizumab) are approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and ravulizumab is approved by the EMA. Many clinicians also use alternative immunotherapies (<a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>) for patients who meet NMOSD diagnostic criteria with or without AQP4-IgG seropositivity. (See <a class="local">'Attack prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of preventive immunotherapy</strong> – Immunosuppression is usually continued for at least five years for patients who are seropositive for AQP4-IgG, including those presenting with a single attack, because they are at high risk for relapse. However, the optimal drug regimen and treatment duration for NMOSD, with or without AQP4 seropositivity, are yet to be determined, and many authorities suggest lifetime treatment. (See <a class="local">'Attack prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The natural history of NMOSD is one of stepwise deterioration due to accumulating visual, motor, sensory, and bladder deficits from recurrent attacks. Long-term disability and mortality rates are high. Although unproven, it is likely that acute and preventive treatment with immunotherapies has improved the long-term outcomes of NMOSD. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17:1019.</a></li><li><a class="nounderline abstract_t">Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 2011; 4:111.</a></li><li><a class="nounderline abstract_t">Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018; 5:e504.</a></li><li><a class="nounderline abstract_t">Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261:1.</a></li><li><a class="nounderline abstract_t">Sherman E, Han MH. Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder. Curr Treat Options Neurol 2015; 17:48.</a></li><li><a class="nounderline abstract_t">Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016; 79:206.</a></li><li><a class="nounderline abstract_t">Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018; 89:346.</a></li><li><a class="nounderline abstract_t">Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord 2012; 1:180.</a></li><li class="breakAll">Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD). https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd.html (Accessed on July 03, 2023).</li><li><a class="nounderline abstract_t">Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 2019; 381:614.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM, Fujihara K, Palace J, et al. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol 2021; 89:1088.</a></li><li><a class="nounderline abstract_t">Frampton JE. Inebilizumab: First Approval. Drugs 2020; 80:1259.</a></li><li class="breakAll">Prescribing information, Uplizna (inebilizumab-cdon) injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf (Accessed on June 15, 2020).</li><li><a class="nounderline abstract_t">Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019; 394:1352.</a></li><li class="breakAll">FDA approves new therapy for rare disease affecting optic nerve, spinal cord. https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-rare-disease-affecting-optic-nerve-spinal-cord (Accessed on June 15, 2020).</li><li class="breakAll">Enspryng (satralizumab-mwge) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf (Accessed on August 17, 2020).</li><li><a class="nounderline abstract_t">Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 2019; 381:2114.</a></li><li><a class="nounderline abstract_t">Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19:402.</a></li><li><a class="nounderline abstract_t">Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS One 2018; 13:e0195909.</a></li><li><a class="nounderline abstract_t">Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol 2023; 93:1053.</a></li><li><a class="nounderline abstract_t">Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris) 2018; 174:255.</a></li><li><a class="nounderline abstract_t">Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017; 264:2003.</a></li><li><a class="nounderline abstract_t">Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19:298.</a></li><li><a class="nounderline abstract_t">Poupart J, Giovannelli J, Deschamps R, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology 2020; 94:e1645.</a></li><li><a class="nounderline abstract_t">Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015; 351:31.</a></li><li><a class="nounderline abstract_t">Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol 2016; 73:1342.</a></li><li><a class="nounderline abstract_t">Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 2020; 19:391.</a></li><li><a class="nounderline abstract_t">Kieseier BC, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013; 70:390.</a></li><li><a class="nounderline abstract_t">Lauenstein AS, Stettner M, Kieseier BC, Lensch E. Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Rep 2014; 2014.</a></li><li><a class="nounderline abstract_t">Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014; 82:1302.</a></li><li><a class="nounderline abstract_t">Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70:394.</a></li><li><a class="nounderline abstract_t">Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol 2015; 72:756.</a></li><li><a class="nounderline abstract_t">Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77:659.</a></li><li><a class="nounderline abstract_t">Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010; 67:1131.</a></li><li><a class="nounderline abstract_t">Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66:1128.</a></li><li><a class="nounderline abstract_t">Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014; 71:1372.</a></li><li><a class="nounderline abstract_t">Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013; 84:918.</a></li><li><a class="nounderline abstract_t">Ramanathan RS, Malhotra K, Scott T. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol 2014; 14:51.</a></li><li><a class="nounderline abstract_t">Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2013; 84:511.</a></li><li><a class="nounderline abstract_t">Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007; 13:968.</a></li><li><a class="nounderline abstract_t">Stellmann JP, Krumbholz M, Friede T, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry 2017; 88:639.</a></li><li><a class="nounderline abstract_t">Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 2019; 32:385.</a></li><li><a class="nounderline abstract_t">Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014; 71:324.</a></li><li><a class="nounderline abstract_t">Zhang C, Tian DC, Yang CS, et al. Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. JAMA Neurol 2017; 74:1010.</a></li><li><a class="nounderline abstract_t">Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007; 13:256.</a></li><li><a class="nounderline abstract_t">Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010; 75:1423.</a></li><li><a class="nounderline abstract_t">Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012; 79:1065.</a></li><li><a class="nounderline abstract_t">Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012; 18:108.</a></li><li><a class="nounderline abstract_t">Juryńczyk M, Zaleski K, Selmaj K. Natalizumab and the development of extensive brain lesions in neuromyelitis optica. J Neurol 2013; 260:1919.</a></li><li><a class="nounderline abstract_t">Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18:113.</a></li><li><a class="nounderline abstract_t">Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010; 12:244.</a></li><li><a class="nounderline abstract_t">Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers 2020; 6:85.</a></li><li><a class="nounderline abstract_t">Papais-Alvarenga RM, Carellos SC, Alvarenga MP, et al. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 2008; 126:12.</a></li><li><a class="nounderline abstract_t">Cabre P, González-Quevedo A, Bonnan M, et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry 2009; 80:1162.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60:848.</a></li><li><a class="nounderline abstract_t">Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol 2004; 251:47.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107.</a></li><li><a class="nounderline abstract_t">Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135:1834.</a></li><li><a class="nounderline abstract_t">Weinstock-Guttman B, Miller C, Yeh E, et al. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler 2008; 14:1061.</a></li><li><a class="nounderline abstract_t">Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70:2197.</a></li><li><a class="nounderline abstract_t">Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59:566.</a></li><li><a class="nounderline abstract_t">Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013; 81:1197.</a></li><li><a class="nounderline abstract_t">Nour MM, Nakashima I, Coutinho E, et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology 2016; 86:79.</a></li><li><a class="nounderline abstract_t">Bourre B, Marignier R, Zéphir H, et al. Neuromyelitis optica and pregnancy. Neurology 2012; 78:875.</a></li><li><a class="nounderline abstract_t">Kim W, Kim SH, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 2012; 78:1264.</a></li><li><a class="nounderline abstract_t">Wang L, Zhou L, ZhangBao J, et al. Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors. J Neurol Neurosurg Psychiatry 2020.</a></li><li><a class="nounderline abstract_t">Collongues N, Alves Do Rego C, Bourre B, et al. Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. Neurology 2021; 96:e2006.</a></li></ol></div><div id="topicVersionRevision">Topic 134223 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20528913" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : EFNS guidelines on diagnosis and management of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21694808" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Current and future treatment approaches for neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345331" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24272588" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433388" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26537743" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29030418" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24555176" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of Neuromyelitis Optica: Review and Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24555176" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of Neuromyelitis Optica: Review and Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31050279" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33586143" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32729016" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Inebilizumab: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32729016" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Inebilizumab: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31495497" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31495497" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31495497" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31774956" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32333898" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29649283" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36866852" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29606320" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28831548" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32199095" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32170036" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of efficacy and tolerability of first-line therapies in NMOSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25727350" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Analysis of the treatment of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27668357" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32333897" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23599943" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24671322" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24634453" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358868" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25985228" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813788" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837859" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neuromyelitis optica treatment: analysis of 36 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19752302" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199960" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23467418" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628894" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23138769" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17623727" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28572277" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30893099" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neuromyelitis optica spectrum disorders: still evolving and broadening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24445513" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28692708" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17439893" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826711" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914835" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Does natalizumab therapy worsen neuromyelitis optica?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868485" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23719787" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Natalizumab and the development of extensive brain lesions in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22146605" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842585" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33093467" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195212" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical course of optic neuritis in patients with relapsing neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762908" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relapsing neuromyelitis optica: long term history and clinical predictors of death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12629245" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neuromyelitis optica: clinical predictors of a relapsing course and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999489" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496275" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The clinical course of neuromyelitis optica (Devic's syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22577216" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573816" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434643" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : NMO-IgG predicts the outcome of recurrent optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453327" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23997151" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26581304" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22402855" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Neuromyelitis optica and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491862" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Influence of pregnancy on neuromyelitis optica spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33219038" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33627499" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
